Per the 2024 CSCO Gastric Cancer Guidelines (9), first-line treatment for metastatic HER2-negative gastric cancer with PD-L1 CPS ≥5 recommends XELOX (capecitabine + oxaliplatin) combined with sintilimab. This evidence concerns the gene CD274 and gastric cancer.